Literature DB >> 22182957

Atrial fibrillation in 2011: Stroke prevention in AF.

Gregory Y H Lip1.   

Abstract

In 2011, key trials with oral factor Xa inhibitors in patients with atrial fibrillation highlighted promising data on these novel anticoagulants. Patients with ≥ 1 stroke risk factors can be considered for oral anticoagulation. These novel, fixed-dose drugs are given without monitoring, so clinicians must learn to balance stroke and bleeding risks.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22182957     DOI： 10.1038/nrcardio.2011.203

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  10 in total

1.  The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?

Authors:  G Karthikeyan; J W Eikelboom
Journal:  Thromb Haemost       Date:  2010-05-10       Impact factor: 5.249

Review 2.  New oral anticoagulant drugs in cardiovascular disease.

Authors:  Ingo Ahrens; Gregory Y H Lip; Karlheinz Peter
Journal:  Thromb Haemost       Date:  2010-06-10       Impact factor: 5.249

3.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

4.  Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis.

Authors:  Gregory Y H Lip; Felicita Andreotti; Laurent Fauchier; Kurt Huber; Elaine Hylek; Eve Knight; Deirdre Lane; Marcel Levi; Francisco Marín; Gualtiero Palareti; Paulus Kirchhof
Journal:  Thromb Haemost       Date:  2011-11-02       Impact factor: 5.249

5.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

6.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

Review 7.  The role of aspirin for stroke prevention in atrial fibrillation.

Authors:  Gregory Y H Lip
Journal:  Nat Rev Cardiol       Date:  2011-07-26       Impact factor: 32.419

Review 8.  Stroke in atrial fibrillation: epidemiology and thromboprophylaxis.

Authors:  G Y H Lip
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

9.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Jesper Lindhardsen; Deirdre A Lane; Ole Ahlehoff; Morten Lock Hansen; Jakob Raunsø; Janne Schurmann Tolstrup; Peter Riis Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  Thromb Haemost       Date:  2011-07-20       Impact factor: 5.249

10.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245
  10 in total
  8 in total

1.  Progress and challenges in the cardiovascular field.

Authors:  Jian-an Wang
Journal:  J Zhejiang Univ Sci B       Date:  2012-08       Impact factor: 3.066

Review 2.  Review And Insights Into The Bleeding Mechanism Incited By Antithrombotic Therapy: Mechanistic Nuances Of Dual Pro-Hemorrhagic Substrate Incorporating Drug-Induced Microvascular Leakage.

Authors:  Petras Stirbys
Journal:  J Atr Fibrillation       Date:  2015-08-31

3.  Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk.

Authors:  Andreas Charidimou; Clare Shakeshaft; David J Werring
Journal:  Front Neurol       Date:  2012-09-19       Impact factor: 4.003

4.  Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2014-07-28

5.  Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.

Authors:  Yana Vinogradova; Carol Coupland; Trevor Hill; Julia Hippisley-Cox
Journal:  BMJ       Date:  2018-07-04

6.  Uptake of direct oral anticoagulants in primary care: an ecological and economic study.

Authors:  Rachel Denholm; Howard Thom; William Hollingworth; Rupert Payne
Journal:  BJGP Open       Date:  2020-06-23

7.  Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study.

Authors:  Dahai Yu; Zhanzheng Zhao; David Simmons
Journal:  Cardiovasc Diabetol       Date:  2020-10-10       Impact factor: 9.951

8.  Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland; Peter Brindle
Journal:  BMJ       Date:  2013-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.